CheckMate 7A8 - Clinical trial • Breast Cancer Foundation NZ

Donate to save lives this Breast Cancer Awareness Month.

CheckMate 7A8

Early Breast Cancer clinical trials for ER+

Recruiting
Updated: July 6, 2020

A study of neoadjuvant nivolumab + palbociclib + anastrozole in post-menopausal women and men with primary breast cancer.

A study of neoadjuvant nivolumab + palbociclib + anastrozole in post-menopausal women and men with primary breast cancer.

Who is it for?

You may be eligible for this study if you meet the below criteria:

  • Participants must have untreated, unilateral, histologically confirmed ER+, HER2- invasive breast cancer with primary tumor =2 cm in largest diameter (cT1-3) in one dimension by clinical or radiographic exam, for whom neoadjuvant endocrine monotherapy deemed to be a suitable therapy.
  • Participants must be deemed eligible for surgery and must agree to undergo surgery after completion of neoadjuvant therapy and agree to provide tumor tissue at baseline, on-treatment, and at surgery.
  • Women must have documented proof that they are not of childbearing potential.
  • Participants must have a performance status (PS) = 1 on the Eastern Cooperative Oncology Group (ECOG) scale.

Study details

Patients will receive either (1) nivolumab + palbociclib + anastrozole (ANZ); (2) palbociclib + ANZ then nivolumab + palbociclib + ANZ; or (3) palbociclib + ANZ.

For full trial information

Australia

Calvary Central Districts Hospital, Elizabeth Vale
Breast Cancer Research Centre, Nedlands

If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.

Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz

Similar clinical trials

For Early Breast Cancer

Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz

Find clinical trials

Interested in a clinical trial?

Subscribe for updates & stay in the loop with new studies.